ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1578896
This article is part of the Research TopicAdvancements in Immune Heterogeneity in Inflammatory Diseases and Cancer: New Targets, Mechanisms, and StrategiesView all 12 articles
The Predictive Value of Naples Prognostic Score for Patients with Locally Advanced Non-small Cell Lung Cancer Undergoing Surgery After Neoadjuvant Chemotherapy
Provisionally accepted
- 1Department of Oncology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China
- 2Department of Infectious diseases, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China
- 3Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, China., Weifang, Shandong Province, China
- 4Jinming Yu Academician Workstation of Oncology, Shandong Second Medical University, Shandong, China, Shandong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective To evaluate the prognostic significance of the Naples Prognostic Score (NPS) in patients with locally advanced non-small cell lung cancer (NSCLC) after neoadjuvant chemotherapy and surgery.Methods A retrospective review was done of 126 patients with locally advanced NSCLC who were surgically treated Affiliated Hospital of Weifang Medical University. from September 2012 to April 2019. According to the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-tomonocyte ratio (LMR), albumin, and total cholesterol before neoadjuvant chemotherapy, NPS was divided into separate groups: group 0, group 1, and group 2. Kaplan-Meier method was used to analyze survival curves for the NPS. Univariate and multivariate Cox analysis of overall survival (OS) and progression-free survival (PFS) was then conducted.This study included 60 male and 66 female patients, with the median age being 59 (59.94±11.77). Based on the NPS system, the three groups were divided: Group 0, 41(32.5%) patients; Group 1, 55(43.7%) patients; and Group 2, 30(23.8%) patients. Smoking status (P=0.032) and KPS score (P=0.018) were significantly different among the three NPS groups, but it had no statistical relevance in regards to gender (P=0.849), age (P=0.474), clinical stage (P=0.101), pathology (P=0.819), tumor location (P=0.304), degree of differentiation (P=0.889), surgical method (P=0.436), chemotherapy (P=0.718), postoperative complications (P=0.177) or CEA level (P=0.447). Univariate Analysis showed that clinical stage (P=0.004), KPS score (P=0.003), surgery approach (P=0.042) and NPS (Group 2 vs. Group 0, P< 0.001; Group 1 vs. Group 0, P=0.005) were predictors of OS in patients with locally advanced NSCLC, and that clinical stage (P=0.005), KPS score (P=0.002), and NPS (Group 2 vs. Group 0, P< 0.001; Group 1 vs. group 0, P=0.001) were significantly associated with PFS. Based on the positive results of univariate analysis, we performed multivariate analysis. Multivariate Cox Regression showed that the NPS was a significant independent predictor of worse OS (Group 2 vs. Group 0, P=0.006; Group 1 vs. group 0, P=0.017) and PFS (group 2 vs. group 0, P=0.006; Group 1 vs group 0, P=0.011). Conclusion As a clinically accessible blood indicator, NPS has vital value in predicting the prognosis of resected locally advanced NSCLC patients receiving neoadjuvant chemotherapy and surgery.
Keywords: Naples prognostic score, NSCLC, Neoadjuvant chemotherapy, NPS, LMR
Received: 18 Feb 2025; Accepted: 30 Apr 2025.
Copyright: © 2025 Zhang, Tang, Li, Wang, Qi and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Li Qi, Department of Infectious diseases, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China
Jingjing Li, Department of Oncology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.